Abstract |
|
Authors | Andreas Schneeweiss, Gunther Bastert, Jens Huober, Diethelm Wallwiener, Rainer Hamerla, Peter Lichter |
Journal | Oncology (Williston Park, N.Y.)
(Oncology (Williston Park))
Vol. 18
Issue 14 Suppl 12
Pg. 27-31
(Dec 2004)
ISSN: 0890-9091 [Print] United States |
PMID | 15685823
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Recombinant Proteins
- Taxoids
- Deoxycytidine
- Granulocyte Colony-Stimulating Factor
- Docetaxel
- Epirubicin
- Filgrastim
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Chemotherapy, Adjuvant
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Docetaxel
- Dose-Response Relationship, Drug
- Epirubicin
(administration & dosage)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Neoadjuvant Therapy
- Recombinant Proteins
- Taxoids
(administration & dosage)
- Time Factors
- Treatment Outcome
- Gemcitabine
|